Figure 1: Incidence of surgical site infection (SSI) in patients undergoing coronary artery bypass graft surgery who were treated with a microbial sealant group compared with the control group. The incidence of SSI was statistically significantly lower in the microbial sealant group than in the control group (2.5% vs. 7.6%, p=0.045).